Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | CDC25B | P30305 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 3/20 | 0.41 |
| ▸ | OGA | O60502 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL649068 | 1.00 | PTPN1 (0.42) | PTPN1CDC25BGSK3BOGAHPGD | |
| SCHEMBL651620 | 0.92 | PTPN1 (0.42) | PTPN1CDC25BGSK3BHPGDPOLB | |
| SCHEMBL651619 | 0.92 | PTPN1 (0.42) | PTPN1CDC25BGSK3BHPGDPOLB | |
| SCHEMBL650359 | 0.90 | HPGD (0.43) | PTPN1CDC25BGSK3BOGAHPGD | |
| SCHEMBL648558 | 0.90 | HPGD (0.43) | PTPN1CDC25BGSK3BOGAHPGD | |
| SCHEMBL651249 | 0.90 | LMNA (0.52) | PTPN1CDC25BGSK3BHPGDPOLB | |
| SCHEMBL651248 | 0.90 | LMNA (0.52) | PTPN1CDC25BGSK3BHPGDPOLB | |
| SCHEMBL648989 | 0.85 | LMNA (0.44) | PTPN1CDC25BGSK3BOGAMAPT | |
| SCHEMBL648988 | 0.85 | LMNA (0.44) | PTPN1CDC25BGSK3BOGAMAPT | |
| SCHEMBL649937 | 0.85 | MEN1 (0.43) | PTPN1GSK3BOGAHPGDPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2423204-A1 | THIAZOLIDINONE DERIVATIVE | SBI Biotech Co., Ltd. (JP) | 2012-02-29 | — | — | EP | disclosed |
| US-8119812-B2 | Thiazolidinone derivative | SBI BIOTECH CO., LTD. (JP) | 2012-02-21 | — | — | US | disclosed |
| US-20110190299-A1 | THIAZOLIDINONE DERIVATIVE | SBI BIOTECH CO., LTD. (JP) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190299-A1 | THIAZOLIDINONE DERIVATIVE | CDC7, CDK17, CDCA2 | PTPN1 1863/4885CDC25B 59/4885GSK3B 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.